Investing.comCodex · 实盘不做把握 5/10不做原因:无增量信息
北京时间·🕒 发布 19:04:36·⟳ 抓取 19:05:31 +55s·⚡ 决策 08-31 19:11:58 +6m27s·56.9 天前
礼来Taltz与Zepbound联合用药52周数据维持银屑病和肥胖获益
不做。当前消息是既有TOGETHER项目的52周延续数据，方向正面但对礼来这种超大市值公司缺少可交易级新增量级；此前1月、2月和3月已披露同项目36周阳性结果及AAD详细数据，短线预期差不足。
📄 原文Investing.com↗ 原文
Lilly’s Taltz and Zepbound combination shows sustained results at one year
Oil rises 3% as U.S. strikes on Iran revive Hormuz supply disruption concerns INDIANAPOLIS - Eli Lilly and Company (NYS…
不做 Eli Lilly and Company（LLY.US）
不做礼来（LLY.US）：52周数据方向正面但属于既有TOGETHER项目延续披露，缺少监管/收入增量和短线可量化edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
礼来披露Taltz与Zepbound联合治疗银屑病疾病合并肥胖的52周结果，临床读数延续正面；但核心有效性信号在2026年1月、2月和3月已由公司新闻稿披露，当前仅是随访维持和未来会议发表安排，未带来监管批准、销售指引、订单或可量化商业增量，因此对LLY.US短线交易edge不足。
消息传播链
- Investing.com转述礼来称联合用药52周维持或改善疾病活动和代谢结局，未见新增商业指引。
- 礼来此前已在AAD相关披露中公布TOGETHER-PsA 36周详细结果，说明核心临床方向早已公开。
- 礼来此前已披露TOGETHER-PsO 36周topline阳性结果，当前52周读数主要是延续验证。
- 礼来此前已披露TOGETHER-PsA 36周topline阳性结果，降低本次消息的预期差。
关键理由
- 52周数据支持Taltz与Zepbound联合治疗在银屑病疾病合并肥胖人群中的疗效持续性。
- 现有产品销售/公司收入基数很大，而本事件未披露新增适应症获批、价格、患者转化率或收入指引，无法估出相对礼来市值有意义的短线增量。
主要风险
- 此前36周阳性结果已于2026年1月、2月和3月公开，当前52周延续数据容易被视为程序性更新。
- 若后续监管同意标签拓展或公司给出明确商业指引，需重新评估而不是沿用本次AVOID。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-01-08 · 影响 weakens
同一临床项目核心36周阳性数据已在2026年初公开，削弱当前52周消息的新鲜预期差。
检索:Lilly Taltz Zepbound TOGETHER 36 week results January February March 2026 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-08-31 · 影响 weakens
当前报道未披露新增收入指引、监管批准或标签拓展，只称详细结果将于未来会议和期刊发表。
检索:Lilly Taltz Zepbound 52 week results revenue guidance label expansion 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足与既有官方披露共同压低置信度和仓位，最终不对礼来开新仓。
方向:临床数据延续性更新方向偏正面，但缺少同市场、同机制且能校准短线涨幅的高相似先例。
涨幅量级:未取得足够高相似先例，且本次没有监管批准或商业化指引，不能据此设定可执行止盈止损。
形态:同一项目多次阶段性披露后，后续延续数据更容易被市场视为低预期差更新。
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
原文全文
展开原文 · 2,076 字
Oil rises 3% as U.S. strikes on Iran revive Hormuz supply disruption concerns
INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY) announced Monday that the combination of Taltz and Zepbound maintained or improved disease activity and metabolic outcomes through 52 weeks in adults with psoriatic disease and obesity, according to a press release statement.
The results come from two Phase 3b clinical trials, TOGETHER-PsO and TOGETHER-PsA, which evaluated the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone. TOGETHER-PsO enrolled 274 adults with moderate-to-severe plaque psoriasis, while TOGETHER-PsA enrolled 271 adults with active psoriatic arthritis. All participants had obesity or overweight with at least one additional weight-related comorbid condition.
At Week 52, 30.6% of patients receiving both drugs in TOGETHER-PsO achieved complete skin clearance plus at least 10% weight loss, compared to 4.4% for Taltz alone. In TOGETHER-PsA, 39.2% of patients receiving combination therapy achieved at least 50% reduction in disease activity plus at least 10% weight loss, versus 1.7% for monotherapy.
Complete skin clearance was achieved by 40.5% of combination therapy patients in TOGETHER-PsO at Week 52, compared to 29.1% for Taltz alone. In TOGETHER-PsA, 43.7% of combination therapy patients achieved at least 50% reduction in disease activity, versus 15.7% for Taltz monotherapy.
Adverse events in the combination treatment arm were generally mild to moderate. The most common side effects reported in at least 5% of participants included nausea, diarrhea, constipation, injection site reactions, vomiting, dizziness and headache.
Taltz is a monoclonal antibody that inhibits interleukin 17A cytokine. Zepbound is a dual GIP and GLP-1 receptor agonist approved for obesity management.
The company stated that detailed 52-week results will be presented at future medical meetings and published in peer-reviewed journals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY) announced Monday that the combination of Taltz and Zepbound maintained or improved disease activity and metabolic outcomes through 52 weeks in adults with psoriatic disease and obesity, according to a press release statement.
The results come from two Phase 3b clinical trials, TOGETHER-PsO and TOGETHER-PsA, which evaluated the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone. TOGETHER-PsO enrolled 274 adults with moderate-to-severe plaque psoriasis, while TOGETHER-PsA enrolled 271 adults with active psoriatic arthritis. All participants had obesity or overweight with at least one additional weight-related comorbid condition.
At Week 52, 30.6% of patients receiving both drugs in TOGETHER-PsO achieved complete skin clearance plus at least 10% weight loss, compared to 4.4% for Taltz alone. In TOGETHER-PsA, 39.2% of patients receiving combination therapy achieved at least 50% reduction in disease activity plus at least 10% weight loss, versus 1.7% for monotherapy.
Complete skin clearance was achieved by 40.5% of combination therapy patients in TOGETHER-PsO at Week 52, compared to 29.1% for Taltz alone. In TOGETHER-PsA, 43.7% of combination therapy patients achieved at least 50% reduction in disease activity, versus 15.7% for Taltz monotherapy.
Adverse events in the combination treatment arm were generally mild to moderate. The most common side effects reported in at least 5% of participants included nausea, diarrhea, constipation, injection site reactions, vomiting, dizziness and headache.
Taltz is a monoclonal antibody that inhibits interleukin 17A cytokine. Zepbound is a dual GIP and GLP-1 receptor agonist approved for obesity management.
The company stated that detailed 52-week results will be presented at future medical meetings and published in peer-reviewed journals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。